Smetanova J, Strizova Z, Sediva A, et al. Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab. Lancet Rheumatol 2022; 4: e163–66—This Comment has been updated to include the following ethics statement: “The study was approved by the Ethics Committee for Multi-Centric Clinical Trials of the University Hospital Motol and 2nd Faculty of Medicine, Charles University in Prague (reference EK-753.1.3/21). All study participants provided written informed consent.” This correction has been made to the online version as of Feb 20, 2023.
. 2023 Feb 20;5(3):e119. doi: 10.1016/S2665-9913(23)00038-3
Correction to Lancet Rheumatol 2022; 4: e163–66
Issue date 2023 Mar.
© 2021 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9940916 PMID: 36844971
This corrects the article "Humoral and cellular immune responses to mRNA COVID-19 vaccines in patients with axial spondyloarthritis treated with adalimumab or secukinumab" in volume 4 on page e163.